Pain in Patients With Dementia and Behavioural Disturbances

August 9, 2011 updated by: University of Bergen

The Impact of Pain on Behavioural Disturbances in Patients With Moderate and Severe Dementia. A Cluster Randomized Trial

In nursing homes (NHs) 80% of the patients have dementia, between 60%-80% exhibit behavioural disturbances (BPSD), and more than 60% have pain. Both pain and BPSD is more common in those with severe dementia. Since older persons with dementia have less communicative skills, suffer from more pain and exhibit more agitation, pain may be a contributing factor in these patients. More than 40% of patients with BPSD are treated with neuroleptics despite described side-effects. There is an urgent need to investigate the impact of individual pain management on BPSD in patients with dementia.

It was hypothesized that

  • pain increase BPSD in patients with dementia
  • individual pain treatment decrease BPSD in patients with dementia

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

We intend to conduct an eight weeks, multi-centre, rater-blinded, cluster randomized, and parallel-group trial, with follow up after four weeks. We will choose cluster randomizing by practical reasons. 920 NH patients were screened and 352 patients with moderate or severe dementia and BPSD were included. The treatment period is 8 weeks, with further follow after four weeks.

The primary outcome measure will be reduction in aggression and agitation as well as other items which are measured by means of CMAI (Cohen Mansfield Agitation Inventory). Secondary outcome are reduction in NPI-NH-subscale agitation/aggression and other items which are measured by the Neuropsychiatric Inventory, Nursing Home Version (NPI-NH). Further, we want to evaluate the concomitant use of acute medication. Additionally, Activities of Daily Living function (ADL) and MIni Mental State Examination (MMSE) will be used as secondary outcome measure.

Pain in patients with dementia will be assessed and followed by the MOBID-2 Pain Scale (secondary outcome measure). MOBID-2 Pain Scale is a staff-administered behavioural instrument for assessment pain in older persons with dementia with god validity and reliability (Husebo 2008, 2009). MOBID-2 is based on patient's pain behaviour in connection with standardised, guided movements of different body part, and pain behaviour related to internal organs, head and skin. Additionally, pain will be registered by pain diagnoses, -etiology, and -duration. The MOBID-2 score is derived from caregiver in a clinical bedside situation during morning care.

Adverse events will be recorded and evaluated throughout the study as the primary assessment of safety and tolerability.

Inclusion criteria: Patients of either gender, 60 years of age or older, living in a nursing home (NH) diagnosed moderate or severe dementia measured by the Functional Assessment Staging (FAST) and MMSE, and BPSD in form of agitation / aggression as measured by subscale of NPI-NH and CMAI.

Exclusion criteria: Patients without cognitive impairment and without BPSD. Patients with hepatic or renal failure or diseases that make it impossible to follow the study schedule.

Study Type

Interventional

Enrollment (Actual)

352

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Norway
    • Horadland
      • Knarvik, Horadland, Norway, 5914
        • Knarvik Nursing Home
    • Hordaland
      • Aastveit, Hordaland, Norway
        • Aastveit Nursing Home
      • Bergen, Hordaland, Norway, 5018
        • Dormkirkehjemmet
      • Bergen, Hordaland, Norway, 5020
        • Fantoft Omsorgssenter
      • Bergen, Hordaland, Norway, 5035
        • Bergen Red Cross Nursing Home
      • Bergen, Hordaland, Norway, 5164
        • Solsletten Sykehjem
      • Bergen, Hordaland, Norway, 5259
        • Mildeheimen
      • Bergen, Hordaland, Norway
        • Søreide Nursing Home
      • Isdalsto, Hordaland, Norway, 5914
        • Lindas bu- og servicecentre
      • Isdalsto, Hordaland, Norway, 5914
        • Saata bu og servicecentre
      • Laksevag, Hordaland, Norway, 5164
        • Lyngbøtunet Nursing Home
      • Nesttun, Hordaland, Norway, 5222
        • Odinsvei Nursing Home
      • Nesttun, Hordaland, Norway, 5223
        • Ovsttunheimen
    • Rogaland
      • Hafrsfjord, Rogaland, Norway, 4042
        • Slaathaug Nursing Home
      • Sandnes, Rogaland, Norway, 4319
        • Rovik Nursing Home
      • Sola, Rogaland, Norway, 4097
        • Sola Nursing Home
      • Stavanger, Rogaland, Norway
        • Blidensol Nursing Home
      • Stavanger, Rogaland, Norway
        • Tasta Nursing Home

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged 65 and older
  • Residing in the NHs for at least 4 weeks
  • Dementia according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (American Psychiatric Association 1994), FAST score > 4 (Hughes 1982).
  • Clinically relevant BPSD, operationally defined as CMAI score ≥ 39 or higher or/and at least one week history of agitation or aggression (Koss 1997).
  • Written, informed consent provided by the participant (if they have capacity) or assent (if they do not have capacity) and a written proxy informed consent from a legally authorized representative empowered to make health-related decisions for the potential study participant.

Exclusion Criteria:

  • Clinician responsible for care, or study clinician considers that the patient suffers from any physical condition, which would make participation in the trial distressing or likely to increase suffering
  • Advanced severe medical disease/disorder with expected survival less than 6 months or that could interfere with participation
  • Psychosis or other severe mental disorder prior to dementia diagnosis;
  • Severe aggression (≥8) on item 3 of the NPI subscale, with aggression as the predominant symptom
  • Schizophrenia, schizoaffective disorder and bipolar disorder
  • Uncontrolled epilepsy
  • Severe liver impairment
  • Renal failure, as measured by or equivalent to an estimated creatinine clearance of < 50mL/min/1.73m,
  • Severe injury or anaemia (Hb < 8.5 mmol/l), comatose state, current enrolment in another experimental protocol.
  • Known allergy or adverse reaction to Paracetamol, Morphine ret, Buprenorphine plaster or pregabalin

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: TRIPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
NO_INTERVENTION: Treatment as usual
Control group
ACTIVE_COMPARATOR: Paracetamol
Intervention group
Drug: Paracetamol
Paracetamol Max. dose: 3g/d
Other Names:
  • Individual pain treatment
ACTIVE_COMPARATOR: Morphine
Intervention group, individual pain treatment
Drug: Morphine
Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d
Other Names:
  • Individual pain treatment
ACTIVE_COMPARATOR: Buprenorphine plaster
Intervention group, individual pain treatment
Drug: Buprenorphine plaster
5ųg/h, change each 7.day; max. dose: 10ųg/h
Other Names:
  • Individual pain treatment
ACTIVE_COMPARATOR: Pregabalin
Intervention group, individual pain treatment
Drug: Pregabalin
25mgx1/d; max 300mg/d
Other Names:
  • individual pain treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cohen-Mansfield Agitation Inventory - long form (CMAI)
Time Frame: CMAI will be used during the screening/inclusion process, at week 2, 4, 8, and 12.
CMAI has 29-item (max. score 203) to assess agitated behaviours in NH-patients. A six-point rating scale assesses the frequency with which patients manifest BPSD evaluating 29 agitated behaviours, ranging from never, less than once a week, but still occurring, once or twice a week, several times a week, once or twice a day, several times a day or several times an hour. Items are presented in four factors: I Aggressive behaviour; II Physical non-aggressive behaviour; III Verbally agitated behavior, IV hiding and hoarding. Ratings are based on face-to-face interviews with caregivers.
CMAI will be used during the screening/inclusion process, at week 2, 4, 8, and 12.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Neuropsychiatric Inventory - Nursing Home Version (NPI-NH)
Time Frame: NPI will be used during the inclusion process, at week 2, 4, 8, and 12.
NPI is a caregiver based interview (10 min.), assessing 10 BPSD and 2 neurovegetative areas with total score and subscales for: delusion, hallucination, agitation, depression, anxiety, disinhibition apathy, irritability, aberrant motor activity, sleep, appetite. Frequency, severity, and caregiver's distress are measured. The NH-version will be used, recently validated in Norwegian (AGS Panel 1998). A higher score reflects increased frequency and severity of the disturbances.
NPI will be used during the inclusion process, at week 2, 4, 8, and 12.
Activity of Daily Living function (ADL)
Time Frame: ADL assessment will be used during clinical investigation related to the inclusion prosess and at week 8
ADL assess physical function. Rating includes activities like feeding, moving, personal toilet, and dressing higher values indicating higher levels of activities of daily functioning and independency (Sheikh 1979). The scale includes 10 items (0-20 score). The ADL score is derived from caregiver interview. Administration of the ADL takes approximately 5 minutes.
ADL assessment will be used during clinical investigation related to the inclusion prosess and at week 8
Mini Mental State Examination
Time Frame: Screening/clinical investigation and week 8
The MMSE is a 30-point mental status examination scale that enables cut-off differentiation for levels of severity of cognitive impairment (Folstein 1975). Cut point for moderate dementia: <20. The question consist of several orientation question (10 points), registration and recall task (6), attention task (5), three stage command (3), two naming task (2), repetition task (1), reading comprehension task (1), written sentence (1), and a visual construction (1). The test takes 15 minutes to administer and the patient is asked the questions directly by the examiner.
Screening/clinical investigation and week 8
Mobilisation-Observation-Behavior-Intensity-Dementia-2 (MOBID-2) Pain Scale
Time Frame: Screening/clinical investigation, week 2,4,8,12
MOBID-2 Pain Scale is a staff-administered behavioural instrument for assessment pain in older persons with dementia (Husebo 2008a). MOBID-2 is based on patient's pain behaviour in connection with standardised, guided movements of different body part, and pain behaviour related to internal organs, head and skin. Additionally, pain will be registered by pain diagnoses, -etiology, and -duration. The MOBID-2 score is derived from caregiver in a clinical bedside situation during morning care. Administration of the MOBID-2 takes approximately 5 minutes.
Screening/clinical investigation, week 2,4,8,12
Functional Assessment Staging (FAST)
Time Frame: Screening and week 8
FAST describes a continuum of seven stages and sub stages from normality to most severe dementia (Hughes 1982). Moderate to severe dementia is consistent with Fast stage of 5 or 6 or 7. Stage 5 is defined as moderately severe cognitive decline, with deficient performance in activities of daily living such as choosing proper clothing and maintaining hygiene. Stage 6 is defined as severe cognitive decline with incontinence and decreased ability to clothe, bathe, toilet oneself, severely limited speech, vocabulary, emotional expression. FAST score is derived from caregiver interview (5 min).
Screening and week 8
Adverse events (AE) and serious adverse event (SAE)
Time Frame: week 2,4,8
Safety and tolerability assessments will consist of monitoring and recording all adverse events (AE) and serious adverse events (SAE) and the regular monitoring of vital signs (BP, puls); AE and SAE registration and report is related to each patient, each medication each centre with reportation to the Norwegian Medicines Agency (study code EUDRACTNR. 2008-007490-20).
week 2,4,8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Bergen

Collaborators

The Research Council of Norway

Investigators

  • Study Director: Rolv Terje Lie, PhD, University of Bergen, Norway
  • Study Chair: Bettina S. Husebo, MD, PhD, University of Bergen, Norway
  • Principal Investigator: Dag Aarsland, MD, Phd, University of Bergen, Norway
  • Principal Investigator: Clive Ballard, MD, PhD, King's College London

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2009

Primary Completion (ACTUAL)

July 1, 2010

Study Completion (ACTUAL)

October 1, 2010

Study Registration Dates

First Submitted

November 27, 2009

First Submitted That Met QC Criteria

November 27, 2009

First Posted (ESTIMATE)

November 30, 2009

Study Record Updates

Last Update Posted (ESTIMATE)

August 10, 2011

Last Update Submitted That Met QC Criteria

August 9, 2011

Last Verified

November 1, 2010

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2008-007490-20

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain

Clinical Trials on Paracetamol

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe